Neovasc Inc. with ticker code (NVCN) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 2.25 and 1.5 calculating the average target price we see 1.88. With the stocks previous close at 0.87 this would indicate that there is a potential upside of 116.1%. The 50 day moving average now sits at 0.82 and the 200 day MA is 1.93. The company has a market cap of $24m. Find out more information at: http://www.neovasc.com
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.